| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -4.6 | -4.2 |
| EPS (diluted, $ a share) | $-0.04 | $-0.06 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: EQ. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Equillium, Inc.: key numbers
- Share price
- $1.15Close, Nov 16
- Market cap
- $94.7M
- Shares outstanding
- 82.32MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Equillium, Inc.
All →Equillium Financial Results
Equillium reported third quarter 2026 financial results, highlighting the initiation of a Phase 1 clinical trial for EQ504 with proof-of-mechanism data expected in Q2 2027. The company strengthened its balance sheet with a $20 million financing tranche closed in October 2026, extending its cash runway into 2029.
“We continue to make important progress advancing EQ504, with the recent initiation of clinical development marking a significant milestone for the program. We believe EQ504’s differentiated immunoregulatory mechanism of action, without broad immune suppression, has the potential to address key epithelial and immune pathways involved in inflammatory disease.”
Bruce Steel, Chief Executive Officer of Equillium
“We look forward to reporting proof-of-mechanism data in the second quarter of 2027, which we expect will inform our planned proof-of-concept study in ulcerative colitis that we expect to initiate in the second half of 2027. Supported by our strong financial position, we remain focused on advancing EQ504 to patients while continuing to evaluate its broader therapeutic potential.”
Bruce Steel, Chief Executive Officer of Equillium
Equillium Capital Raise of $20M
Equillium triggered a $20 million milestone closing of a previously announced private placement following the dosing of the first patient in its Phase 1 clinical trial of EQ504. The company is issuing approximately 14.9 million shares and 20.1 million pre-funded warrants to institutional and accredited investors. The proceeds are expected to extend the company's cash runway into 2029.
- Value
- $20M
Equillium Regulatory Approval
Equillium received clearance from the Therapeutic Goods Administration in Australia under the Clinical Trial Notification scheme to initiate a Phase 1 clinical trial of EQ504. The study will evaluate the safety and pharmacokinetics of the oral drug in healthy participants, with dosing expected to begin in early November 2026.